Clinical Trials
New medicines would not be possible without patient participation in clinical trials; we are grateful to all those who make progress possible.
New medicines would not be possible without patient participation in clinical trials; we are grateful to all those who make progress possible.
At KalVista, we are focused on developing new oral treatments for HAE. Learn more about our clinical studies.
The KONFIDENT Study (KVD900-301) was a Phase 3 clinical trial of sebetralstat for the oral, on-demand treatment of hereditary angioedema (HAE) attacks. The KONFIDENT Study is completed, and positive topline Phase 3 data results were reported in February 2024.
The KONFIDENT-S (KVD900-302) is an open-label extension trial evaluating the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with HAE type I or type II.
The KONFIDENT-KID (KVD900-303) is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. A total of 36 patients were enrolled from 2-11 years of age across seven countries in North America, Europe, and Asia. KONFIDENT-KID will collect safety, pharmacokinetics, and efficacy data for each patient for up to one year and features a proprietary pediatric oral disintegrating tablet (ODT) formulation of sebetralstat.
YOU ARE NOW LEAVING KALVISTA.COM
You are now being directed to another KalVista website that contains information about specific treatment(s)